List of Excipients in Branded Drug UP AND UP TIOCONAZOLE 1

Generic Drugs Containing UP AND UP TIOCONAZOLE 1

Company	Ingredient	NDC	Excipient
Target Corporation	tioconazole	11673-426	BUTYLATED HYDROXYANISOLE
Target Corporation	tioconazole	11673-426	MAGNESIUM ALUMINUM SILICATE
Target Corporation	tioconazole	11673-426	PETROLATUM

What are the Most Frequently-Used Excipients in UP AND UP TIOCONAZOLE 1?

# Of NDCs	Excipient
1	BUTYLATED HYDROXYANISOLE
1	MAGNESIUM ALUMINUM SILICATE
1	PETROLATUM

Up & Up Tioconazole 1 Excipient Strategy and Commercial Opportunities

Last updated: August 4, 2026

Up & Up Tioconazole 1 is a single-dose, over-the-counter vaginal antifungal product containing tioconazole 6.5% in an ointment base. Its commercial value comes from low-cost private-label distribution, simple dosing, and broad pharmacy and mass-retail availability rather than from pharmaceutical composition patents. The strongest opportunities are in applicator design, leakage control, packaging, adherence, retailer differentiation, and line extensions.

What is Up & Up Tioconazole 1?

Up & Up Tioconazole 1 is Target’s private-label version of a one-day vaginal antifungal treatment. The product is used for the treatment of vaginal yeast infections caused by Candida species.

Attribute	Product detail
Retail brand	Up & Up
Active ingredient	Tioconazole 6.5%
Dosage form	Vaginal ointment
Route	Intravaginal
Dose regimen	One single-use application
Regulatory category	OTC vaginal antifungal
Primary channel	Mass retail and pharmacy
Reference commercial category	Tioconazole 1-day vaginal treatment
Main competitors	Monistat 1, generic tioconazole products, store-brand vaginal antifungals

The FDA permits tioconazole vaginal products under the OTC vaginal antifungal framework when they meet the applicable monograph conditions, labeling, dosage, and concentration requirements. The product does not depend on a new-drug approval strategy comparable to a branded prescription product. FDA OTC Monograph M030 covers vaginal antifungal drug products, including applicable labeling and formulation requirements. [1]

What excipients are used in Up & Up Tioconazole 1?

Public product labeling identifies Up & Up Tioconazole 1 as an ointment formulation using a hydrophobic base. The listed inactive ingredients are mineral oil and petrolatum. [2]

Excipient	Functional role	Commercial and technical relevance
Mineral oil	Emollient, solvent, and vehicle component	Supports spreadability and hydrophobic drug delivery
Petrolatum	Occlusive ointment base	Increases residence time and reduces rapid washout

The excipient strategy is deliberately minimal. A mineral oil-petrolatum system can provide several advantages for a single-dose vaginal product:

1. It creates a water-resistant vehicle that remains in contact with vaginal tissue.
2. It avoids the complexity of a multi-component emulsion.
3. It reduces manufacturing and quality-control burden.
4. It supports a low-cost private-label product.
5. It limits the number of excipients that may cause irritation or compatibility problems.

This formulation approach is consistent with the product’s commercial positioning: one application, low manufacturing complexity, and broad consumer accessibility.

How does the tioconazole ointment base affect product performance?

The excipient base controls drug distribution, retention, consumer perception, and packaging requirements.

Residence time and drug exposure

Petrolatum is highly occlusive and does not dissolve readily in vaginal fluid. Mineral oil can improve the ointment’s fluidity and spreadability. Together, the excipients can help maintain tioconazole at the site of infection after a single administration.

The tradeoff is that a hydrophobic base may feel greasy, may leak after administration, and may create staining concerns. Those attributes can affect consumer satisfaction even when clinical efficacy remains acceptable.

Dose delivery

The applicator must deliver the full labeled dose of ointment. A high-viscosity base increases the risk of residual product remaining inside the applicator or of incomplete expulsion at lower temperatures.

Important quality attributes include:

• Fill weight
• Tioconazole content uniformity
• Ointment viscosity
• Extrusion force
• Applicator residual volume
• Product homogeneity
• Container-closure integrity
• Stability under heat exposure

Packaging compatibility

Mineral oil and petrolatum can interact with certain plastics, elastomers, and adhesives. Packaging development should assess:

• Swelling or softening of applicator components
• Extractables and leachables
• Seal integrity
• Label adhesion
• Cap and nozzle compatibility
• Leakage during transport
• Stability at elevated temperature

The product’s single-use format reduces repeated opening and microbial-contamination risk. It also limits the amount of packaging required per treatment course.

What formulation patents protect Up & Up Tioconazole 1?

No product-specific formulation patent can be confirmed from the public OTC label alone. Up & Up Tioconazole 1 is an OTC private-label product, and its public labeling does not establish a proprietary patent estate.

The likely intellectual-property position is as follows:

IP category	Relevance to Up & Up Tioconazole 1
Tioconazole active-ingredient patent	Commercially unlikely to be relevant because tioconazole is an established generic active
Composition-of-matter patent	Expected to be expired or commercially irrelevant
Orange Book-listed patent	No confirmed product-specific Orange Book patent identified from the public OTC label
Paragraph IV challenge	Generally not applicable to an OTC monograph private-label product
Method-of-use patent	Limited value because the indication is established and monograph-based
Ointment formulation patent	Possible only if a supplier or manufacturer owns a separate formulation patent
Applicator patent	Potentially relevant if the device has proprietary geometry or dosing technology
Manufacturing patent	Possible for specialized mixing, filling, or packaging processes
Trademark rights	Up & Up brand rights remain commercially important

Does Up & Up Tioconazole 1 have Orange Book protection?

Up & Up Tioconazole 1 does not appear to compete through an Orange Book exclusivity strategy. The product is marketed as an OTC vaginal antifungal under FDA’s nonprescription framework rather than as a newly approved prescription NDA with active Orange Book patent listings.

The absence of Orange Book protection does not eliminate all IP risk. A manufacturer could still face claims involving:

• A patented applicator
• A patented package or dispensing system
• A proprietary manufacturing process
• Trade secrets relating to bulk ointment production
• Contractual restrictions imposed by a formulation supplier
• Trademark or trade-dress disputes

When does Up & Up Tioconazole 1 lose exclusivity?

Up & Up Tioconazole 1 does not have a conventional patent exclusivity expiration date. Its commercial exclusivity is based on retailer branding, supply arrangements, shelf placement, price, and distribution.

The product competes in a market where multiple manufacturers can supply tioconazole vaginal products if they comply with the applicable FDA OTC requirements. The practical barriers to entry are therefore operational rather than patent-based:

• FDA-compliant formulation
• Validated manufacturing process
• Reliable tioconazole supply
• Compatible single-use applicator
• Retailer authorization
• Product liability coverage
• Stable packaging and distribution
• Consumer trust in the store brand

A competitor does not generally need to wait for an Up & Up patent expiration date before launching a compliant tioconazole product.

Are there Paragraph IV challenges to Up & Up Tioconazole 1?

A Paragraph IV challenge is unlikely to be the relevant pathway for this product. Paragraph IV certifications apply to generic applicants referencing an approved drug listed in the FDA’s Approved Drug Products with Therapeutic Equivalence Evaluations, commonly called the Orange Book. [3]

An OTC monograph product is not ordinarily challenged through the same patent-certification mechanism used for an abbreviated new drug application. A competitor seeking market entry would more likely:

1. Develop a compliant OTC monograph product.
2. Establish manufacturing and quality systems.
3. Secure a private-label or branded distribution agreement.
4. Complete required FDA registration and listing steps.
5. Launch through retail, pharmacy, or e-commerce channels.

What commercial opportunities exist in the excipient strategy?

The current formulation is cost-efficient but leaves room for product differentiation. The most attractive opportunities are not necessarily new active ingredients. They are improvements to delivery, comfort, packaging, and consumer communication.

1. Low-leakage ointment systems

A supplier could develop a modified hydrophobic base with improved residence time and lower post-dose leakage. The opportunity would require balancing:

• Retention
• Spreadability
• Extrusion force
• Residue
• Staining
• Stability
• Compatibility with latex and synthetic condoms

A formulation that reduces mess without compromising drug release could command a premium over basic store-brand products.

2. Consumer-preferred semi-solid systems

A cream, gel, or emulsion could offer better sensory characteristics than a petrolatum-heavy ointment. Potential benefits include easier insertion and less greasy residue.

The principal development risks are:

• Changes in tioconazole solubility
• Reduced physical stability
• Phase separation
• Preservative requirements
• Greater microbial-control burden
• Different release characteristics
• New packaging requirements

A new dosage form would need to remain within the applicable FDA regulatory framework or undergo a different regulatory review.

3. Applicator optimization

The applicator is an important commercial opportunity because the product is administered once and the consumer directly experiences the device.

Potential improvements include:

• Lower actuation force
• More complete dose expulsion
• Rounded insertion tip
• Improved grip
• Reduced residual volume
• Tamper evidence
• Applicator geometry that minimizes leakage
• Packaging that separates the applicator from the outer carton

A proprietary applicator could create defensible IP even where the drug and excipient base are generic.

4. Dual-pack and symptom-management bundles

Retailers could offer a tioconazole treatment with adjunct products such as:

• External anti-itch cream
• Unscented cleansing products
• Comfort wipes
• Panty liners
• Educational inserts directing consumers to seek medical advice for recurrent or atypical symptoms

Any bundle must avoid implying that an adjunct product treats the infection unless its labeling supports that claim.

5. Private-label tiering

Retailers could create multiple product tiers:

Tier	Product concept	Commercial objective
Value	Basic tioconazole 1-day ointment	Defend price-sensitive shoppers
Core	Improved applicator and packaging	Increase store-brand conversion
Premium	Low-leakage or comfort-oriented formulation	Support higher margin
Digital	E-commerce multipack	Increase repeat purchase and basket size

The active ingredient could remain unchanged while the retailer differentiates through delivery system and user experience.

How does Up & Up Tioconazole 1 compare with competing products?

Product category	Active ingredient	Typical regimen	Main differentiator
Tioconazole 1-day	Tioconazole 6.5%	One dose	Convenience and single application
Miconazole 1-day	Miconazole nitrate	One dose	Direct branded competition
Miconazole 3-day	Miconazole nitrate	Three doses	Lower intensity per application
Miconazole 7-day	Miconazole nitrate	Seven doses	Longer, lower-dose course
Prescription oral therapy	Fluconazole or other agent	Product-specific	Physician-directed treatment

The commercial advantage of tioconazole 1-day products is regimen simplicity. The disadvantages are higher per-application drug load, ointment mess, and consumer confusion between yeast infection symptoms and other causes of vaginal irritation.

Up & Up competes primarily on price and availability against national brands. Its largest strategic vulnerability is limited brand differentiation beyond the retailer relationship.

What regulatory issues affect excipient commercialization?

The FDA OTC monograph framework imposes constraints on active ingredient, concentration, indication, warnings, directions, and labeling. A reformulated product cannot assume that a new vehicle is commercially interchangeable with the existing ointment.

Key regulatory issues include:

• Whether the new dosage form remains within the monograph
• Whether the excipient is suitable for vaginal administration
• Whether the formulation changes drug release
• Whether the product remains bioequivalent or otherwise acceptable
• Whether the labeling must change
• Whether the applicator is a medical device component requiring additional controls
• Whether new stability, compatibility, or performance data are necessary

The product must also comply with current good manufacturing practice requirements under 21 C.F.R. Parts 210 and 211. [4]

What manufacturing and IP barriers affect market entry?

Manufacturing barriers are moderate, but they are higher than the active ingredient alone suggests. A prospective supplier needs validated controls for heating, mixing, deaeration, filling, and single-use packaging.

Manufacturing risks

• Incomplete dispersion of tioconazole
• Air entrapment during filling
• Variable fill weight
• Ointment hardening during storage
• Nozzle blockage
• Applicator leakage
• Temperature-driven viscosity shifts
• Container interaction
• Batch-to-batch sensory variation

IP and contracting risks

The principal IP risk may arise from the delivery system rather than the tioconazole formulation. A manufacturer should evaluate patents covering:

• Single-dose vaginal applicators
• Pre-filled dispensing devices
• Low-residual-volume applicators
• Vaginal drug-delivery systems
• Ointment packaging
• Child-resistant or tamper-evident closures
• Specialized filling methods

A freedom-to-operate review should cover the United States, Canada, Europe, and other intended markets because device and packaging patents can have different geographic scope.

What revenue exposure does the product create?

Up & Up Tioconazole 1 is unlikely to be a major revenue driver relative to prescription or specialty medicines, but it can have strategic value for a retailer and contract manufacturer.

Revenue depends on:

• Retail distribution breadth
• Private-label penetration
• Seasonal demand
• Price relative to Monistat
• E-commerce availability
• Stock-out frequency
• Multipack adoption
• Gross margin on store-brand products
• Ability to cross-sell adjacent personal-care products

For Target, the product can support pharmacy traffic and private-label penetration. For a contract manufacturer, the value lies in repeat volume, retailer access, and the potential to supply multiple store brands using a common validated platform.

Public sources do not establish product-level sales for Up & Up Tioconazole 1. Retailer financial filings generally report broader category or segment results rather than individual OTC SKUs.

Key Takeaways

• Up & Up Tioconazole 1 contains tioconazole 6.5% in a single-dose vaginal ointment.
• The public label identifies mineral oil and petrolatum as the principal inactive ingredients. [2]
• The hydrophobic excipient system supports retention and low-cost manufacture but can create leakage and greasiness.
• The product does not rely on a conventional Orange Book patent or Paragraph IV exclusivity strategy.
• Commercial exclusivity is driven by Target’s private-label distribution, price, shelf placement, and supply reliability.
• The strongest product-development opportunities involve applicator engineering, reduced leakage, improved sensory performance, packaging, and retailer tiering.
• The main IP risks are likely to involve applicators, packaging, manufacturing processes, and supplier contracts rather than tioconazole itself.
• A reformulation must be assessed against FDA OTC monograph requirements and applicable manufacturing controls.

FAQs About Up & Up Tioconazole 1

Is Up & Up Tioconazole 1 the same type of product as Vagistat-1?

Yes. Both are one-day vaginal antifungal products based on tioconazole 6.5%. The manufacturer, packaging, excipient details, and commercial terms may differ.

Can a company launch a competing tioconazole 1-day product without waiting for patent expiration?

Generally, a company can pursue an OTC monograph-compliant product without a conventional patent-clearance event tied to the Up & Up brand. It still must evaluate formulation, applicator, packaging, manufacturing, trademark, and supplier IP.

Is petrolatum a commercially important excipient in vaginal antifungal products?

Yes. Petrolatum provides an occlusive, hydrophobic base that can improve residence time. Its disadvantages include greasiness, leakage, staining, and compatibility concerns with certain materials.

Could a new tioconazole gel obtain premium pricing?

Possibly, if the gel improves comfort, leakage, spreadability, and dose delivery while maintaining acceptable stability and regulatory status. A change in dosage form may increase development and regulatory costs.

What is the most defensible innovation area for a private-label tioconazole product?

The applicator and packaging system are likely to offer the clearest differentiation. A lower-force, low-residual-volume applicator with improved leakage control can improve consumer experience without changing the active ingredient.

References

1. U.S. Food and Drug Administration. (2022). OTC Monograph M030: Vaginal Antifungal Drug Products for Over-the-Counter Human Use. https://www.fda.gov

2. DailyMed. (n.d.). Up and Up Tioconazole 1: Tioconazole 6.5% vaginal ointment product labeling. National Library of Medicine. https://dailymed.nlm.nih.gov

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov

4. Electronic Code of Federal Regulations. (2024). 21 C.F.R. Parts 210 and 211: Current good manufacturing practice for drugs. https://www.ecfr.gov